A Phase 3 interventional study of Tirzepatide and Placebo in Obesity, sponsored by Eli Lilly and Company. Completed at 18 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-07-16.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.
Among the 104 studies testing tirzepatide in Obesity, this one is the 26th largest by enrollment, is one of 6 that started in 2021, is one of 26 in phase 3, and was the 9th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:
McMaster University · Sites in Canada
Ages 18–60
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Eli Lilly and Company · Sites in United States, Belgium, Israel and 7 more countries
Ages 6–11
Eli Lilly and Company · Sites in United States
Ages 18–70
Columbia University · Sites in United States
Ages 40+
By country, each count listing its studies:
Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, tirzepatide is the treatment under test here. Read study by study →
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 24 · Phase 3 28 · Phase 4 29
First in 2019; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 267 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 69 across the 104 interventional studies. Of the 23 that completed or were terminated, 14 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 104 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 59th largest by enrollment of the 117 interventional ones that give a count, is one of 8 that started in 2021, is one of 51 in phase 3, and was the 10th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
34 of the studies testing tirzepatide in Obesity that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07738276Phase 3Shahid Beheshti University of Medical SciencesEvaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity | 2027-06-11 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
Add all 34 to your calendar (.ics) → With an account.
Among the 104 studies testing tirzepatide in Obesity, from their registry updates:
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to learn more about tirzepatide in participants with obesity disease. The study will also measure how Tirzepatide affects body weight with a low-calorie diet and increased physical activity. The study will last around 72 Weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).
Drug: Tirzepatide
Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.
Drug: Tirzepatide
Participants received matching placebo administered SC QW.
Other: Placebo
Administered SC
Also known as: LY3298176
Administered SC
Mean Percent Change in Body Weight
Mean percent change in body weight was measured. Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with Baseline + impaired glucose tolerance (IGT) at Screening + Hyperlipidemia at Screening + non-alcoholic fatty liver disease (NAFLD) at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, 72 Weeks
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
Time frame: Week 72
Percentage of Participants Who Had Improvement in Obesity-related Health Problems
Percentage of participants who had improvement in obesity-related health problems
Time frame: Week 72
Change From Baseline in Fasting Glucose for Participants With IGT at Baseline
Change from Baseline in Fasting Glucose for Participants with IGT at Baseline. LS mean was determined by MMRM model with = Baseline + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Change From Baseline in Oral Glucose Tolerance (OGTT) 2-hr Glucose for Participants With Impaired Glucose Tolerance (IGT) at Baseline
Change from Baseline in OGTT 2-hr Glucose for Participants with IGT at Baseline. LS mean was determined by MMRM model with Baseline + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Percent Change From Baseline in Fasting Lipids [Triglycerides (TG)] for Participants With Hyperlipidemia at Baseline
Percent Change from Baseline in Fasting Lipids TG for Participants with Hyperlipidemia at Baseline. LS mean was determined by MMRM model with log (Baseline) + NAFLD at Screening + IGT at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Percent Change From Baseline in Hepatic Fat Fraction (HFF) for Participants With Non-alcoholic Fatty Liver Disease [NAFLD]
Percent Change from Baseline in HFF for participants diagnosed as NAFLD by MRI at Baseline. LS mean was determined by ANCOVA model with Baseline + Hyperlipidemia at Screening + IGT at Screening + Sex + Treatment (Type III sum of squares) as variables. Percent Change from Baseline in HFF for participants with NAFLD is reported. NAFLD was diagnosed by Magnetic Resonance Imaging (MRI) at Baseline. This was evaluated only for participants who were diagnosed with NAFLD at baseline by MRI.
Time frame: Baseline, Week 72
Percentage of Participants Who Achieved Improvements of IGT
Percentage of Participants Who Achieved Improvements of IGT. This was evaluated only for participants with IGT at baseline.
Time frame: Week 72
Percentage of Participants Who Achieved Improvements of Hyperlipidemia
Percentage of Participants Who Achieved Improvements of Hyperlipidemia. This was evaluated only for participants with hyperlipidemia at baseline.
Time frame: Week 72
Percentage of Participants Who Achieved Improvements of NAFLD
Percentage of Participants Who Achieved Improvements of NAFLD. This was evaluated only for participants who were diagnosed as NAFLD by MRI at Baseline.
Time frame: Week 72
Percentage of Participants Who Achieve ≥10% Body Weight Reduction
Percentage of Participants Who Achieve ≥10% body weight reduction.
Time frame: Week 72
Percentage of Participants Who Achieve ≥15% Body Weight Reduction
Percentage of Participants Who Achieve ≥15% body weight reduction.
Time frame: Week 72
Change From Baseline in Absolute Body Weight
Change from Baseline in Absolute Body Weight. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Change From Baseline in Body Mass Index (BMI)
Change from Baseline in BMI. LS mean was determined using MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Percent Change From Baseline in Visceral Adipose Tissue (VAT)
Percent Change from Baseline in VAT. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Percent Change From Baseline in Subcutaneous Adipose Tissue (SAT)
Percent Change from Baseline in SAT. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Change From Baseline in VAT/SAT Ratio
Change from Baseline in VAT/SAT Ratio. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Percentage of Participants Who Achieved VAT <100 Square Centimeter (cm²) From Baseline for Participants With VAT≥100 cm² at Baseline
Percentage of Participants Who Achieve VAT \<100 cm² from Baseline for participants with VAT≥100 cm² at Baseline.
Time frame: Week 72
Change From Baseline in Waist Circumference
Change from Baseline in Waist Circumference. LS mean was determined using MMRM model with = Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Change From Baseline in Hemoglobin A1c (HbA1c)
Change from Baseline in HbA1c was assessed only for Participants with IGT at Baseline. LS mean was determined using MMRM model with = Baseline + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Change From Baseline in Fasting Insulin for Participants With IGT at Baseline
Change from Baseline in Fasting Insulin for Participants with IGT at Baseline. LS mean was determined using MMRM model log(Baseline) + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Change From Baseline in Systolic Blood Pressure
Change from Baseline in Systolic Blood Pressure. LS mean was determined using MMRM model with Baseline + Hyperlipidemia at Screening + NAFLD at Screening + IGT at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Change From Baseline in Diastolic Blood Pressure
Change from Baseline in Diastolic Blood Pressure. LS mean was determined using MMRM model with Baseline + Hyperlipidemia at Screening + NAFLD at Screening + IGT at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Change From Baseline in Short Form 36 Version 2 Health Survey (SF-36v2) Acute Form Physical Functioning Domain Score
The SF-36v2 acute form, 1-week recall assesses participants' health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Information from these 8 domains is further aggregated into 2 health component summary scores: Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths. Scoring of each domain and both summary scores are norm based and presented in the form of T scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores. LS mean was determined using ANCOVA model with Week 0 (Visit 3) + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Change From Baseline in Impact of Weight on Quality-of-Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score
The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. LS mean was determined using ANCOVA model with Week 0 (Visit 3) + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
Change From Baseline in Euro Quality of Life Five Dimensions (EQ-5D-5L)
The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It comprises of 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, unable to perform/extreme problems). In addition to the health profile, a single health state index value can be derived based on a formula that attaches weights to each of the levels in each dimension. This index value ranges between ˂0 (where 0 is a health state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health). LS mean was determined using ANCOVA model with Week 0 (Visit 3) + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment (Type III sum of squares) as variables.
Time frame: Baseline, Week 72
267 participants were randomized in the study. However, due to good clinical practice (GCP) compliance issues identified at one of the investigative sites, all 42 participants from that site were excluded from the study analyses
| Milestone | 10 Milligrams (mg) Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Started | 88 | 90 | 89 |
| Received at least 1 dose of study drug (excluding the gcp compliance investigative site) | 73 | 77 | 75 |
| Completed | 60 | 65 | 67 |
| Not completed | 28 | 25 | 22 |
| Withdrew: Adverse event | 7 | 8 | 5 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 3 | 3 |
| Withdrew: Participants excluded due to gcp compliance issue | 15 | 13 | 14 |
Mean percent change in body weight was measured. Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with Baseline + impaired glucose tolerance (IGT) at Screening + Hyperlipidemia at Screening + non-alcoholic fatty liver disease (NAFLD) at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| Percent change | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Mean Percent Change in Body Weight | -17.8 ± 0.94 | -22.7 ± 0.90 | -1.7 ± 0.90 |
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
| Percentage of participants | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieve ≥5% Body Weight Reduction | 94.37 | 96.05 | 20 |
Percentage of participants who had improvement in obesity-related health problems
| Percentage of participants | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Percentage of Participants Who Had Improvement in Obesity-related Health Problems | 70.0 | 79.69 | 11.11 |
Change from Baseline in Fasting Glucose for Participants with IGT at Baseline. LS mean was determined by MMRM model with = Baseline + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| milligrams per deciliter (mg/dL) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Change From Baseline in Fasting Glucose for Participants With IGT at Baseline | -12.81 ± 1.490 | -10.61 ± 1.391 | 2.19 ± 1.291 |
Change from Baseline in OGTT 2-hr Glucose for Participants with IGT at Baseline. LS mean was determined by MMRM model with Baseline + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| milligrams per deciliter (mg/dL) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Change From Baseline in Oral Glucose Tolerance (OGTT) 2-hr Glucose for Participants With Impaired Glucose Tolerance (IGT) at Baseline | -61.50 ± 5.330 | -70.56 ± 4.951 | -5.74 ± 4.612 |
Percent Change from Baseline in Fasting Lipids TG for Participants with Hyperlipidemia at Baseline. LS mean was determined by MMRM model with log (Baseline) + NAFLD at Screening + IGT at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| Percent change | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Fasting Lipids [Triglycerides (TG)] for Participants With Hyperlipidemia at Baseline | -47.3 ± 3.34 | -50.6 ± 2.77 | -11.0 ± 5.14 |
Percent Change from Baseline in HFF for participants diagnosed as NAFLD by MRI at Baseline. LS mean was determined by ANCOVA model with Baseline + Hyperlipidemia at Screening + IGT at Screening + Sex + Treatment (Type III sum of squares) as variables. Percent Change from Baseline in HFF for participants with NAFLD is reported. NAFLD was diagnosed by Magnetic Resonance Imaging (MRI) at Baseline. This was evaluated only for participants who were diagnosed with NAFLD at baseline by MRI.
| Percent change | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Hepatic Fat Fraction (HFF) for Participants With Non-alcoholic Fatty Liver Disease [NAFLD] | -63.9 ± 3.09 | -69.9 ± 2.99 | -19.6 ± 3.05 |
Percentage of Participants Who Achieved Improvements of IGT. This was evaluated only for participants with IGT at baseline.
| Percentage of participants | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved Improvements of IGT | 92.50 | 97.83 | 28.0 |
Percentage of Participants Who Achieved Improvements of Hyperlipidemia. This was evaluated only for participants with hyperlipidemia at baseline.
| Percentage of participants | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved Improvements of Hyperlipidemia | 72.41 | 81.08 | 25 |
Percentage of Participants Who Achieved Improvements of NAFLD. This was evaluated only for participants who were diagnosed as NAFLD by MRI at Baseline.
| Percentage of participants | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved Improvements of NAFLD | 69.49 | 77.42 | 9.84 |
Percentage of Participants Who Achieve ≥10% body weight reduction.
| Percentage of participants | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieve ≥10% Body Weight Reduction | 85.92 | 92.11 | 4 |
Percentage of Participants Who Achieve ≥15% body weight reduction.
| Percentage of participants | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieve ≥15% Body Weight Reduction | 63.38 | 82.89 | 1.33 |
Change from Baseline in Absolute Body Weight. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| kilograms (kg) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Change From Baseline in Absolute Body Weight | -16.0 ± 0.86 | -20.8 ± 0.82 | -1.5 ± 0.82 |
Change from Baseline in BMI. LS mean was determined using MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| kilograms per metres squared (kg/m^2) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Change From Baseline in Body Mass Index (BMI) | -5.8 ± 0.32 | -7.7 ± 0.30 | -0.6 ± 0.30 |
Percent Change from Baseline in VAT. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| Percent change | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Visceral Adipose Tissue (VAT) | -39.4 ± 2.44 | -44.5 ± 2.37 | -3.4 ± 2.42 |
Percent Change from Baseline in SAT. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| Percent change | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Subcutaneous Adipose Tissue (SAT) | -32.2 ± 1.90 | -36.5 ± 1.85 | -5.0 ± 1.90 |
Change from Baseline in VAT/SAT Ratio. LS mean was determined by MMRM model with Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| ratio | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Change From Baseline in VAT/SAT Ratio | -0.09 ± 0.023 | -0.08 ± 0.023 | 0.01 ± 0.023 |
Percentage of Participants Who Achieve VAT \<100 cm² from Baseline for participants with VAT≥100 cm² at Baseline.
| Percentage of participants | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Percentage of Participants Who Achieved VAT <100 Square Centimeter (cm²) From Baseline for Participants With VAT≥100 cm² at Baseline | 26.32 | 37.10 | 1.64 |
Change from Baseline in Waist Circumference. LS mean was determined using MMRM model with = Baseline + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| centimeters (cm) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Change From Baseline in Waist Circumference | -12.7 ± 0.88 | -16.6 ± 0.83 | -1.3 ± 0.84 |
Change from Baseline in HbA1c was assessed only for Participants with IGT at Baseline. LS mean was determined using MMRM model with = Baseline + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| Percentage of HbA1c | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | -0.67 ± 0.045 | -0.68 ± 0.042 | -0.02 ± 0.039 |
Change from Baseline in Fasting Insulin for Participants with IGT at Baseline. LS mean was determined using MMRM model log(Baseline) + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| milli-international units/liter (mIU/L) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Change From Baseline in Fasting Insulin for Participants With IGT at Baseline | -6.04 ± 0.517 | -6.69 ± 0.433 | -2.13 ± 0.776 |
Change from Baseline in Systolic Blood Pressure. LS mean was determined using MMRM model with Baseline + Hyperlipidemia at Screening + NAFLD at Screening + IGT at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| millimeters of Mercury (mmHg) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure | -11.2 ± 1.42 | -12.0 ± 1.35 | 1.9 ± 1.35 |
Change from Baseline in Diastolic Blood Pressure. LS mean was determined using MMRM model with Baseline + Hyperlipidemia at Screening + NAFLD at Screening + IGT at Screening + Sex + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.
| millimeters of Mercury (mmHg) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Change From Baseline in Diastolic Blood Pressure | -5.9 ± 1.09 | -6.3 ± 1.04 | 0.5 ± 1.04 |
The SF-36v2 acute form, 1-week recall assesses participants' health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Information from these 8 domains is further aggregated into 2 health component summary scores: Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths. Scoring of each domain and both summary scores are norm based and presented in the form of T scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores. LS mean was determined using ANCOVA model with Week 0 (Visit 3) + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment (Type III sum of squares) as variables.
| Score on a scale | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Change From Baseline in Short Form 36 Version 2 Health Survey (SF-36v2) Acute Form Physical Functioning Domain Score | 1.1 ± 0.39 | 2.0 ± 0.37 | -0.1 ± 0.37 |
The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. All items in the physical domain are rated on either a 5-point frequency ("never" to "always") scale or a 5-point truth ("not at all true" to "completely true") scale. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. LS mean was determined using ANCOVA model with Week 0 (Visit 3) + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment (Type III sum of squares) as variables.
| Score on a scale | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Change From Baseline in Impact of Weight on Quality-of-Life Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score | 15.2 ± 2.05 | 13.0 ± 1.95 | 2.2 ± 1.96 |
The EQ-5D-5L is a standardized instrument used to measure self-reported health status of the participants. It comprises of 5 dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). There are 5 response levels (no problems, slight problems, moderate problems, severe problems, unable to perform/extreme problems). In addition to the health profile, a single health state index value can be derived based on a formula that attaches weights to each of the levels in each dimension. This index value ranges between ˂0 (where 0 is a health state equivalent to death; negative values are valued as worse than dead) to 1 (perfect health). LS mean was determined using ANCOVA model with Week 0 (Visit 3) + IGT at Screening + Hyperlipidemia at Screening + NAFLD at Screening + Sex + Treatment (Type III sum of squares) as variables.
| Score on a scale | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Change From Baseline in Euro Quality of Life Five Dimensions (EQ-5D-5L) | 0.01 ± 0.011 | 0.01 ± 0.011 | -0.01 ± 0.011 |
Collected over Baseline Through Safety Follow-Up (Up To 76 Weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 10 mg Tirzepatide | 0/73 (0%) | 8/73 (11%) | 59/73 (80.8%) |
| 15 mg Tirzepatide | 0/77 (0%) | 5/77 (6.5%) | 65/77 (84.4%) |
| Placebo | 0/75 (0%) | 5/75 (6.7%) | 51/75 (68%) |
| Event | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| Endometrial adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/30 | 1/32 | 0/30 |
| Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/30 | 1/32 | 0/30 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/43 | 0/45 | 0/45 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/43 | 0/45 | 1/45 |
| Rhegmatogenous retinal detachmentEye disorders | 1/73 | 0/77 | 0/75 |
| Large intestine polypGastrointestinal disorders | 1/73 | 0/77 | 0/75 |
| Covid-19Infections and infestations | 1/73 | 0/77 | 0/75 |
| GastroenteritisInfections and infestations | 1/73 | 0/77 | 0/75 |
| Pneumonia bacterialInfections and infestations | 1/73 | 0/77 | 0/75 |
| Brain stem infarctionNervous system disorders | 1/73 | 0/77 | 0/75 |
| Event | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 12/73 | 21/77 | 5/75 |
| NauseaGastrointestinal disorders | 10/73 | 18/77 | 3/75 |
| Covid-19Infections and infestations | 15/73 | 15/77 | 13/75 |
| PyrexiaGeneral disorders | 10/73 | 11/77 | 11/75 |
| DiarrhoeaGastrointestinal disorders | 9/73 | 7/77 | 3/75 |
| Decreased appetiteMetabolism and nutrition disorders | 9/73 | 6/77 | 1/75 |
| VomitingGastrointestinal disorders | 5/73 | 9/77 | 3/75 |
| NasopharyngitisInfections and infestations | 7/73 | 1/77 | 8/75 |
| Abdominal discomfortGastrointestinal disorders | 5/73 | 4/77 | 0/75 |
| HeadacheNervous system disorders | 2/73 | 2/77 | 5/75 |
All participants, excluding the GCP compliance investigative site, who received at least one dose of study drug.
| Age, Continuous(years) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| Mean | 49.00 ± 10.87 | 51.10 ± 10.30 | 52.30 ± 10.93 | 50.80 ± 10.74 |
| Sex: Female, Male(Participants) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| Female | 30 | 32 | 30 | 92 |
| Male | 43 | 45 | 45 | 133 |
| Ethnicity (NIH/OMB)(Participants) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 73 | 77 | 75 | 225 |
| Race (NIH/OMB)(Participants) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 73 | 77 | 75 | 225 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 10 mg Tirzepatide | 15 mg Tirzepatide | Placebo | Total |
|---|---|---|---|---|
| Japan | 73 | 77 | 75 | 225 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2021 to primary completion in Jun 2023, 25 months.
Results were first posted in Jul 2024, 1 year after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 25 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide